Leap Therapeutics (LPTX) Competitors $2.91 +0.13 (+4.68%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends LPTX vs. CDXC, ZVRA, ARCT, CRVS, SIGA, KOD, VERV, GHRS, YMAB, and KRROShould you be buying Leap Therapeutics stock or one of its competitors? The main competitors of Leap Therapeutics include ChromaDex (CDXC), Zevra Therapeutics (ZVRA), Arcturus Therapeutics (ARCT), Corvus Pharmaceuticals (CRVS), SIGA Technologies (SIGA), Kodiak Sciences (KOD), Verve Therapeutics (VERV), GH Research (GHRS), Y-mAbs Therapeutics (YMAB), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry. Leap Therapeutics vs. ChromaDex Zevra Therapeutics Arcturus Therapeutics Corvus Pharmaceuticals SIGA Technologies Kodiak Sciences Verve Therapeutics GH Research Y-mAbs Therapeutics Korro Bio ChromaDex (NASDAQ:CDXC) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership, community ranking and risk. Is CDXC or LPTX more profitable? ChromaDex has a net margin of 1.62% compared to Leap Therapeutics' net margin of 0.00%. ChromaDex's return on equity of 4.85% beat Leap Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ChromaDex1.62% 4.85% 2.70% Leap Therapeutics N/A -116.24%-93.18% Which has higher valuation & earnings, CDXC or LPTX? ChromaDex has higher revenue and earnings than Leap Therapeutics. Leap Therapeutics is trading at a lower price-to-earnings ratio than ChromaDex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChromaDex$91.67M4.57-$4.94M$0.01549.00Leap Therapeutics$1.50M74.34-$81.41M-$1.93-1.51 Which has more volatility and risk, CDXC or LPTX? ChromaDex has a beta of 2.16, meaning that its share price is 116% more volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Does the MarketBeat Community prefer CDXC or LPTX? ChromaDex received 249 more outperform votes than Leap Therapeutics when rated by MarketBeat users. However, 68.94% of users gave Leap Therapeutics an outperform vote while only 64.37% of users gave ChromaDex an outperform vote. CompanyUnderperformOutperformChromaDexOutperform Votes54264.37% Underperform Votes30035.63% Leap TherapeuticsOutperform Votes29368.94% Underperform Votes13231.06% Do analysts prefer CDXC or LPTX? ChromaDex currently has a consensus price target of $8.00, indicating a potential upside of 45.72%. Leap Therapeutics has a consensus price target of $7.50, indicating a potential upside of 157.73%. Given Leap Therapeutics' higher probable upside, analysts clearly believe Leap Therapeutics is more favorable than ChromaDex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ChromaDex 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Leap Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to CDXC or LPTX? In the previous week, ChromaDex had 1 more articles in the media than Leap Therapeutics. MarketBeat recorded 1 mentions for ChromaDex and 0 mentions for Leap Therapeutics. ChromaDex's average media sentiment score of 0.22 beat Leap Therapeutics' score of 0.00 indicating that ChromaDex is being referred to more favorably in the media. Company Overall Sentiment ChromaDex Neutral Leap Therapeutics Neutral Do institutionals and insiders hold more shares of CDXC or LPTX? 15.4% of ChromaDex shares are held by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are held by institutional investors. 9.6% of ChromaDex shares are held by insiders. Comparatively, 5.4% of Leap Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryChromaDex beats Leap Therapeutics on 12 of the 17 factors compared between the two stocks. Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office... I put all the details together for you here — but please hurry. Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPTX vs. The Competition Export to ExcelMetricLeap TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$111.51M$6.57B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio-1.5110.4289.5817.17Price / Sales74.34195.801,116.12116.95Price / CashN/A57.1642.8237.86Price / Book1.245.094.774.78Net Income-$81.41M$151.83M$120.15M$225.60M7 Day Performance-1.36%-2.13%-1.92%-1.23%1 Month Performance13.67%-3.10%11.47%3.36%1 Year Performance-7.91%11.54%30.54%16.60% Leap Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPTXLeap Therapeutics1.2939 of 5 stars$2.91+4.7%$7.50+157.7%-1.0%$111.51M$1.50M-1.5140Positive NewsGap DownCDXCChromaDex4.5929 of 5 stars$6.10-0.3%$8.00+31.1%+283.9%$465.94M$91.67M620.00106Analyst DowngradeZVRAZevra Therapeutics2.9108 of 5 stars$8.52+0.5%$21.00+146.5%+78.9%$454.76M$24.49M-4.3065ARCTArcturus Therapeutics2.5583 of 5 stars$16.70-3.0%$66.75+299.7%-49.7%$452.35M$142.47M-7.75180Analyst ForecastNews CoverageCRVSCorvus Pharmaceuticals2.2299 of 5 stars$7.01-5.0%$12.83+83.1%+219.9%$450.44MN/A-7.8030Options VolumeNews CoverageHigh Trading VolumeSIGASIGA Technologies1.6071 of 5 stars$6.29+1.8%N/A+4.6%$449.11M$139.92M5.1540KODKodiak Sciences2.2957 of 5 stars$8.51+0.5%$8.00-6.0%+210.0%$447.83MN/A-2.3290Gap DownVERVVerve Therapeutics1.9678 of 5 stars$5.28-7.5%$25.75+387.7%-57.7%$447.01M$11.76M-2.32110GHRSGH Research1.1215 of 5 stars$8.58+10.9%$35.67+315.7%+28.8%$446.40MN/A-9.8010Positive NewsYMABY-mAbs Therapeutics2.249 of 5 stars$9.95+5.5%$20.89+109.9%+35.7%$445.66M$84.82M-17.46150KRROKorro Bio1.2659 of 5 stars$47.43+1.2%$142.17+199.7%-21.8%$444.42M$14.07M0.0070 Related Companies and Tools Related Companies ChromaDex Alternatives Zevra Therapeutics Alternatives Arcturus Therapeutics Alternatives Corvus Pharmaceuticals Alternatives SIGA Technologies Alternatives Kodiak Sciences Alternatives Verve Therapeutics Alternatives GH Research Alternatives Y-mAbs Therapeutics Alternatives Korro Bio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LPTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leap Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LPTX Stock Alerts